07 April 2004 00:32
Shreya Life To Add Specialty, Therapeutic Products
Shreya Life Sciences Pvt Ltd, has proposed to launch a slew of products in specialty and therapeutic segment over a
period of time thereby scaling up its sales turnover to Rs 500 crore by the end of year 2005-06. The company is a
subsidiary of Moscow-based $340 million Shreya Corporation. "We are in the process of acquiring two pharma
companies, which will help us to capture a major marketshare in the therapeutics and specialty segments," Mr
Amitava Sengupta, sales manager, Shreya Life Sciences, told FE. The acquisition will help in doubling the sales turnover
from the targeted Rs 190 crore achieved during this fiscal. It may be mentioned that the company tookover the erstwhile
pharma division of Rallis India Ltd in August 2001 and acquired Indore-based Plethico Ltd about six months ago. The new
products proposed to be launched include a painless injectable human insulin besides drugs for rheumatic arthrities,
spasmodic drug for children, and a component used during an ophthalmic surgery, Mr Sengupta said. We are banking on the
painless injectable insulin injection targeting a wider market, and hence, set up a manufacturing unit with a capacity
to generate one month’s requirement in a day, he added. The product portfolio of the company include drugs for
gastro-intestinal care, pain management, nutritional care, surgical and emergency care and antibiotics. The new product
launched in the basket is TD-36, a brand of Tadalafil for erectile dysfunction, which has been approved and licensed for
usage in the US and other European countries.
[Financial Express] |
RUSSIA IN FACTS
